Tevogen Bio/$TVGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tevogen Bio
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.
Ticker
$TVGN
Sector
Primary listing
Employees
18
Headquarters
Website
Tevogen Bio Metrics
BasicAdvanced
$41m
-
-$6.48
0.10
-
Price and volume
Market cap
$41m
Beta
0.1
52-week high
$12.03
52-week low
$4.14
Average daily volume
36k
Financial strength
Current ratio
0.295
Quick ratio
0.117
Long term debt to equity
-76.142
Total debt to equity
-96.246
Interest coverage (TTM)
-87.46%
Profitability
EBITDA (TTM)
-21.005
Management effectiveness
Return on assets (TTM)
-294.43%
Return on equity (TTM)
243.19%
Valuation
Price to book
-2.17
Price to tangible book (TTM)
-2.17
Price to free cash flow (TTM)
-2.778
Free cash flow yield (TTM)
-36.00%
Free cash flow per share (TTM)
-3.492
Growth
Earnings per share change (TTM)
-36.71%
3-year earnings per share growth (CAGR)
-48.75%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs